マウスモデル技術の世界市場：技術別 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

当レポートでは、世界のマウスモデル技術市場について調査分析し、市場動向、セグメント分析、地域分析、企業プロファイルなどを提供しています。

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界のマウスモデル技術市場

第4章 市場の概要

• イントロダクション
  • セグメントの定義
• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 世界のマウスモデル技術市場の分析と予測（2017年～2031年）
  • 市場収益予測

第5章 主な考察

• 世界の遺伝子改変マウスモデルの概要
• 規制シナリオ：地域別、世界
• 技術の進歩
• 主な業界イベント（合併、買収、パートナーシップ、提携など）
• 業界に対するCOVID-19パンデミックの影響（バリューチェーンと短期・中期・長期の影響）

第6章 世界のマウスモデルテクノロジー市場の分析と予測：技術別

• イントロダクションと定義
• 主な調査結果/発展
• 市場金額の予測：技術別（2017年～2031年）
  • CRISPRノックアウト
  • CRISPRノックイン
  • ランダム挿入
  • 大規模ターゲット挿入
  • ES細胞改変（相同組換え）
  • その他
• 市場の魅力：技術別

第7章 世界のマウスモデルテクノロジー市場の分析と予測：エンドユーザー別

• イントロダクションと定義
• 主な調査結果/発展
• 市場金額の予測：エンドユーザー別（2017年～2031年）
  • 製薬企業
  • バイオテクノロジー企業
  • 学術・研究施設
  • 開発・製造受託機関
• 市場の魅力：エンドユーザー別

第8章 世界のマウスモデルテクノロジー市場の分析と予測：地域別

• 主な調査結果
• 市場金額の予測：地域別
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ
• 市場の魅力：国/地域別

第9章 北米のマウスモデル技術市場の分析と予測

• イントロダクション
  • 主な調査結果
• 市場金額の予測：技術別（2017年～2031年）
• 市場金額の予測：エンドユーザー別（2017年～2031年）
• 市場金額の予測：技術別（2017年～2031年）
• 市場金額の予測：国別（2017年～2031年）
  • 米国
  • カナダ
• 市場魅力分析

第10章 欧州のマウスモデル技術市場の分析と予測

第11章 アジア太平洋のマウスモデル技術市場の分析と予測

第12章 ラテンアメリカのマウスモデル技術市場の分析と予測

第13章 中東・アフリカのマウスモデル技術市場の分析と予測

第14章 競合情勢

• 市場企業 - 競合マトリックス：階層・企業規模別
• 市場シェア分析：企業別（2021年）
• 企業プロファイル
  • BIOCYTOGEN
  • Charles River Laboratories
  • Cyagen Biosciences
  • Gempharmatech
  • genOway
  • ingenious targeting laboratory
  • Merck KGaA
  • Ozgene Pty Ltd.
  • Taconic Biosciences, Inc.
  • PolyGene AG
  • THE JACKSON LABORATORY
  • Yale School of Medicine
  • University of North Carolina
  • University of Nebraska Medical Center
  • Monash University
  • UMass Chan Medical School
  • University of Bonn
  • Columbia University
  • The University of Arizona

List of Tables

• Table 01: Price/Cost Analysis of Mice Models, by Region
• Table 02: Global Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017-2031
• Table 03: Global Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 04: Global Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
• Table 05: Global Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
• Table 06: Global Mice Model Technologies Market Value (US$ Mn) Forecast, Academic and Research Facilities by Technology, 2017-2031
• Table 07: Global Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017-2031
• Table 08: Global Mice Model Technologies Market Value (US$ Mn) Forecast, by Region, 2017-2031
• Table 09: North America Mice Model Technologies Market Value (US$ Mn) Forecast, by Country, 2017-2031
• Table 10: North America Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017-2031
• Table 11: North America Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 12: North America Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
• Table 13: North America Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
• Table 14: North America Mice Model Technologies Market Value (US$ Mn) Forecast, Academic and Research Facilities by Technology, 2017-2031
• Table 15: North America Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017-2031
• Table 16: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
• Table 17: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017-2031
• Table 18: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 19: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
• Table 20: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
• Table 21: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, Academic and Research Facilities by Technology, 2017-2031
• Table 22: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017-2031
• Table 23: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 24: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017-2031
• Table 25: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 26: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
• Table 27: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
• Table 28: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, Academic and Research Facilities by Technology, 2017-2031
• Table 29: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017-2031
• Table 30: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 31: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017-2031
• Table 32: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 33: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
• Table 34: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
• Table 35: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017-2031
• Table 36: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017-2031
• Table 37: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 38: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017-2031
• Table 39: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 40: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
• Table 41: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
• Table 42: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, Academic and Research Facilities by Technology, 2017-2031
• Table 43: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017-2031

List of Figures

• Figure 01: Global Mice Model Technologies Market Value (US$ Mn) Forecast, 2017-2031
• Figure 02: Mice Model Technologies Market Value Share, by Technology, 2021
• Figure 03: Mice Model Technologies Market Value Share, by End-user, 2021
• Figure 04: Mice Model Technologies Market Value Share, by Region, 2021
• Figure 05: Global Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031
• Figure 06: Global Mice Model Technologies Market Attractiveness Analysis, by Technology, 2022-2031
• Figure 07: Global Mice Model Technologies Market Value (US$ Mn), by CRISPR Knockout, 2017-2031
• Figure 08: Global Mice Model Technologies Market Value (US$ Mn), by CRISPR Knockin Mice, 2017-2031
• Figure 09: Global Mice Model Technologies Market Value (US$ Mn), by Random Insertions, 2017-2031
• Figure 10: Global Mice Model Technologies Market Value (US$ Mn), by Large, Targeted Insertions, 2017-2031
• Figure 11: Global Mice Model Technologies Market Value (US$ Mn), by ES Cell Modification (Homologous Recombination), 2017-2031
• Figure 12: Global Mice Model Technologies Market Value (US$ Mn), by Others, 2017-2031
• Figure 13: Global Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031
• Figure 14: Global Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 15: Global Mice Model Technologies Market Value (US$ Mn), by Pharmaceutical Companies, 2017-2031
• Figure 16: Global Mice Model Technologies Market Value (US$ Mn), by Biotechnology Companies, 2017-2031
• Figure 17: Global Mice Model Technologies Market Value (US$ Mn), by Academic and Research Facilities, 2017-2031
• Figure 18: Global Mice Model Technologies Market Value (US$ Mn), by Contract Research and Manufacturing Organizations, 2017-2031
• Figure 19: Global Mice Model Technologies Market Value Share Analysis, by Region, 2021 and 2031
• Figure 20: Global Mice Model Technologies Market Attractiveness Analysis, by Region, 2022-2031
• Figure 21: North America Mice Model Technologies Market Value (US$ Mn) Forecast, 2017-2031
• Figure 22: North America Mice Model Technologies Market Attractiveness Analysis, by Country, 2022-2031
• Figure 23: North America Mice Model Technologies Market Value Share Analysis, by Country, 2021 and 2031
• Figure 24: North America Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031
• Figure 25: North America Mice Model Technologies Market Attractiveness Analysis, by Technology, 2022-2031
• Figure 26: North America Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031
• Figure 27: North America Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 28: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, 2017-2031
• Figure 29: Europe Mice Model Technologies Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 30: Europe Mice Model Technologies Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
• Figure 31: Europe Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031
• Figure 32: Europe Mice Model Technologies Market Attractiveness Analysis, by Technology, 2022-2031
• Figure 33: Europe Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031
• Figure 34: Europe Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 35: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, 2017-2031
• Figure 36: Asia Pacific Mice Model Technologies Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 37: Asia Pacific Mice Model Technologies Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
• Figure 38: Asia Pacific Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031
• Figure 39: Asia Pacific Mice Model Technologies Market Attractiveness Index, by Technology, 2022-2031
• Figure 40: Asia Pacific Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031
• Figure 41: Asia Pacific Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 42: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, 2017-2031
• Figure 43: Latin America Mice Model Technologies Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031
• Figure 44: Latin America Mice Model Technologies Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
• Figure 45: Latin America Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031
• Figure 46: Latin America Mice Model Technologies Market Attractiveness Analysis, by Technology, 2022-2031
• Figure 47: Latin America Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031
• Figure 48: Latin America Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 49: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, 2017-2031
• Figure 50: Middle East & Africa Mice Model Technologies Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031
• Figure 51: Middle East & Africa Mice Model Technologies Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
• Figure 52: Middle East & Africa Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031
• Figure 53: Middle East & Africa Mice Model Technologies Market Attractiveness Analysis, by Technology, 2022-2031
• Figure 54: Middle East & Africa Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031
• Figure 55: Middle East & Africa Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022-2031

The report provides revenue of the global mice model technologies market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global mice model technologies market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the mice model technologies market.

The report delves into the competitive landscape of the global mice model technologies market. Key players operating in the global mice model technologies market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global mice model technologies market profiled in this report.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Mice Model Technologies Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Mice Model Technologies Market Analysis and Forecasts, 2017-2031
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Global Genetically Engineered Mouse Model Overview
• 5.2. Regulatory Scenario by Region/globally
• 5.3. Technological Advancements
• 5.4. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
• 5.5. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Mice Model Technologies Market Analysis and Forecasts, By Technology

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Technology, 2017-2031
  • 6.3.1. CRISPR Knockout
  • 6.3.2. CRISPR Knockin
  • 6.3.3. Random Insertions
  • 6.3.4. Large, Targeted Insertions
  • 6.3.5. ES Cell Modification (Homologous Recombination)
  • 6.3.6. Others
• 6.4. Market Attractiveness By Technology

7. Global Mice Model Technologies Market Analysis and Forecasts, By End-user

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By End-user, 2017-2031
  • 7.3.1. Pharmaceutical Companies
  • 7.3.2. Biotechnology Companies
  • 7.3.3. Academic and Research Facilities
  • 7.3.4. Contract Research and Manufacturing Organizations
• 7.4. Market Attractiveness By End-user

8. Global Mice Model Technologies Market Analysis and Forecasts, By Region

• 8.1. Key Findings
• 8.2. Market Value Forecast By Region
  • 8.2.1. North America
  • 8.2.2. Europe
  • 8.2.3. Asia Pacific
  • 8.2.4. Latin America
  • 8.2.5. Middle East & Africa
• 8.3. Market Attractiveness By Country/Region

9. North America Mice Model Technologies Market Analysis and Forecast

• 9.1. Introduction
  • 9.1.1. Key Findings
• 9.2. Market Value Forecast By Technology, 2017-2031
  • 9.2.1. CRISPR Knockout
  • 9.2.2. CRISPR Knockin
  • 9.2.3. Random Insertions
  • 9.2.4. Large, Targeted Insertions
  • 9.2.5. ES Cell Modification (Homologous Recombination)
  • 9.2.6. Others
• 9.3. Market Value Forecast By End-user, 2017-2031
  • 9.3.1. Pharmaceutical Companies
  • 9.3.2. Biotechnology Companies
  • 9.3.3. Academic and Research Facilities
  • 9.3.4. Contract Research and Manufacturing Organizations
• 9.4. Market Value Forecast By End-user by Technology, 2017-2031
  • 9.4.1. Pharmaceutical Companies
    • 9.4.1.1. CRISPR Knockout
    • 9.4.1.2. CRISPR Knockin
    • 9.4.1.3. Random Insertions
    • 9.4.1.4. Large, Targeted Insertions
    • 9.4.1.5. ES Cell Modification (Homologous Recombination)
    • 9.4.1.6. Others
  • 9.4.2. Biotechnology Companies
    • 9.4.2.1. CRISPR Knockout
    • 9.4.2.2. CRISPR Knockin
    • 9.4.2.3. Random Insertions
    • 9.4.2.4. Large, Targeted Insertions
    • 9.4.2.5. ES Cell Modification (Homologous Recombination)
    • 9.4.2.6. Others
  • 9.4.3. Academic and Research Facilities
    • 9.4.3.1. CRISPR Knockout
    • 9.4.3.2. CRISPR Knockin
    • 9.4.3.3. Random Insertions
    • 9.4.3.4. Large, Targeted Insertions
    • 9.4.3.5. ES Cell Modification (Homologous Recombination)
    • 9.4.3.6. Others
  • 9.4.4. Contract Research and Manufacturing Organizations
    • 9.4.4.1. CRISPR Knockout
    • 9.4.4.2. CRISPR Knockin
    • 9.4.4.3. Random Insertions
    • 9.4.4.4. Large, Targeted Insertions
    • 9.4.4.5. ES Cell Modification (Homologous Recombination)
    • 9.4.4.6. Others
• 9.5. Market Value Forecast By Country, 2017-2031
  • 9.5.1. U.S.
  • 9.5.2. Canada
• 9.6. Market Attractiveness Analysis
  • 9.6.1. By Technology
  • 9.6.2. By End-user
  • 9.6.3. By End-user by Technology
  • 9.6.4. By Country

10. Europe Mice Model Technologies Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Technology, 2017-2031
  • 10.2.1. CRISPR Knockout
  • 10.2.2. CRISPR Knockin
  • 10.2.3. Random Insertions
  • 10.2.4. Large, Targeted Insertions
  • 10.2.5. ES Cell Modification (Homologous Recombination)
  • 10.2.6. Others
• 10.3. Market Value Forecast By End-user, 2017-2031
  • 10.3.1. Pharmaceutical Companies
  • 10.3.2. Biotechnology Companies
  • 10.3.3. Academic and Research Facilities
  • 10.3.4. Contract Research and Manufacturing Organizations
• 10.4. Market Value Forecast By End-user by Technology, 2017-2031
  • 10.4.1. Pharmaceutical Companies
    • 10.4.1.1. CRISPR Knockout
    • 10.4.1.2. CRISPR Knockin
    • 10.4.1.3. Random Insertions
    • 10.4.1.4. Large, Targeted Insertions
    • 10.4.1.5. ES Cell Modification (Homologous Recombination)
    • 10.4.1.6. Others
  • 10.4.2. Biotechnology Companies
    • 10.4.2.1. CRISPR Knockout
    • 10.4.2.2. CRISPR Knockin
    • 10.4.2.3. Random Insertions
    • 10.4.2.4. Large, Targeted Insertions
    • 10.4.2.5. ES Cell Modification (Homologous Recombination)
    • 10.4.2.6. Others
  • 10.4.3. Academic and Research Facilities
    • 10.4.3.1. CRISPR Knockout
    • 10.4.3.2. CRISPR Knockin
    • 10.4.3.3. Random Insertions
    • 10.4.3.4. Large, Targeted Insertions
    • 10.4.3.5. ES Cell Modification (Homologous Recombination)
    • 10.4.3.6. Others
  • 10.4.4. Contract Research and Manufacturing Organizations
    • 10.4.4.1. CRISPR Knockout
    • 10.4.4.2. CRISPR Knockin
    • 10.4.4.3. Random Insertions
    • 10.4.4.4. Large, Targeted Insertions
    • 10.4.4.5. ES Cell Modification (Homologous Recombination)
    • 10.4.4.6. Others
• 10.5. Market Value Forecast By Country/Sub-Region, 2017-2031
  • 10.5.1. Germany
  • 10.5.2. U.K.
  • 10.5.3. France
  • 10.5.4. Spain
  • 10.5.5. Italy
  • 10.5.6. Rest of Europe
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Technology
  • 10.6.2. By End-user
  • 10.6.3. By End-user by Technology
  • 10.6.4. By Country/Sub-Region

11. Asia Pacific Mice Model Technologies Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Technology, 2017-2031
  • 11.2.1. CRISPR Knockout
  • 11.2.2. CRISPR Knockin
  • 11.2.3. Random Insertions
  • 11.2.4. Large, Targeted Insertions
  • 11.2.5. ES Cell Modification (Homologous Recombination)
  • 11.2.6. Others
• 11.3. Market Value Forecast By End-user, 2017-2031
  • 11.3.1. Pharmaceutical Companies
  • 11.3.2. Biotechnology Companies
  • 11.3.3. Academic and Research Facilities
  • 11.3.4. Contract Research and Manufacturing Organizations
• 11.4. Market Value Forecast By End-user by Technology, 2017-2031
  • 11.4.1. Pharmaceutical Companies
    • 11.4.1.1. CRISPR Knockout
    • 11.4.1.2. CRISPR Knockin
    • 11.4.1.3. Random Insertions
    • 11.4.1.4. Large, Targeted Insertions
    • 11.4.1.5. ES Cell Modification (Homologous Recombination)
    • 11.4.1.6. Others
  • 11.4.2. Biotechnology Companies
    • 11.4.2.1. CRISPR Knockout
    • 11.4.2.2. CRISPR Knockin
    • 11.4.2.3. Random Insertions
    • 11.4.2.4. Large, Targeted Insertions
    • 11.4.2.5. ES Cell Modification (Homologous Recombination)
    • 11.4.2.6. Others
  • 11.4.3. Academic and Research Facilities
    • 11.4.3.1. CRISPR Knockout
    • 11.4.3.2. CRISPR Knockin
    • 11.4.3.3. Random Insertions
    • 11.4.3.4. Large, Targeted Insertions
    • 11.4.3.5. ES Cell Modification (Homologous Recombination)
    • 11.4.3.6. Others
  • 11.4.4. Contract Research and Manufacturing Organizations
    • 11.4.4.1. CRISPR Knockout
    • 11.4.4.2. CRISPR Knockin
    • 11.4.4.3. Random Insertions
    • 11.4.4.4. Large, Targeted Insertions
    • 11.4.4.5. ES Cell Modification (Homologous Recombination)
    • 11.4.4.6. Others
• 11.5. Market Value Forecast By Country/Sub-Region, 2017-2031
  • 11.5.1. China
  • 11.5.2. Japan
  • 11.5.3. India
  • 11.5.4. Australia & New Zealand
  • 11.5.5. Rest of Asia Pacific
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Technology
  • 11.6.2. By End-user
  • 11.6.3. By End-user by Technology
  • 11.6.4. By Country/Sub-Region

12. Latin America Mice Model Technologies Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Technology, 2017-2031
  • 12.2.1. CRISPR Knockout
  • 12.2.2. CRISPR Knockin
  • 12.2.3. Random Insertions
  • 12.2.4. Large, Targeted Insertions
  • 12.2.5. ES Cell Modification (Homologous Recombination)
  • 12.2.6. Others
• 12.3. Market Value Forecast By End-user, 2017-2031
  • 12.3.1. Pharmaceutical Companies
  • 12.3.2. Biotechnology Companies
  • 12.3.3. Academic and Research Facilities
  • 12.3.4. Contract Research and Manufacturing Organizations
• 12.4. Market Value Forecast By End-user by Technology, 2017-2031
  • 12.4.1. Pharmaceutical Companies
    • 12.4.1.1. CRISPR Knockout
    • 12.4.1.2. CRISPR Knockin
    • 12.4.1.3. Random Insertions
    • 12.4.1.4. Large, Targeted Insertions
    • 12.4.1.5. ES Cell Modification (Homologous Recombination)
    • 12.4.1.6. Others
  • 12.4.2. Biotechnology Companies
    • 12.4.2.1. CRISPR Knockout
    • 12.4.2.2. CRISPR Knockin
    • 12.4.2.3. Random Insertions
    • 12.4.2.4. Large, Targeted Insertions
    • 12.4.2.5. ES Cell Modification (Homologous Recombination)
    • 12.4.2.6. Others
  • 12.4.3. Academic and Research Facilities
    • 12.4.3.1. CRISPR Knockout
    • 12.4.3.2. CRISPR Knockin
    • 12.4.3.3. Random Insertions
    • 12.4.3.4. Large, Targeted Insertions
    • 12.4.3.5. ES Cell Modification (Homologous Recombination)
    • 12.4.3.6. Others
  • 12.4.4. Contract Research and Manufacturing Organizations
    • 12.4.4.1. CRISPR Knockout
    • 12.4.4.2. CRISPR Knockin
    • 12.4.4.3. Random Insertions
    • 12.4.4.4. Large, Targeted Insertions
    • 12.4.4.5. ES Cell Modification (Homologous Recombination)
    • 12.4.4.6. Others
• 12.5. Market Value Forecast By Country/Sub-Region, 2017-2031
  • 12.5.1. Brazil
  • 12.5.2. Mexico
  • 12.5.3. Rest of Latin America
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Technology
  • 12.6.2. By End-user
  • 12.6.3. By End-user by Technology
  • 12.6.4. By Country/Sub-Region

13. Middle East & Africa Mice Model Technologies Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Technology, 2017-2031
  • 13.2.1. CRISPR Knockout
  • 13.2.2. CRISPR Knockin
  • 13.2.3. Random Insertions
  • 13.2.4. Large, Targeted Insertions
  • 13.2.5. ES Cell Modification (Homologous Recombination)
  • 13.2.6. Others
• 13.3. Market Value Forecast By End-user, 2017-2031
  • 13.3.1. Pharmaceutical Companies
  • 13.3.2. Biotechnology Companies
  • 13.3.3. Academic and Research Facilities
  • 13.3.4. Contract Research and Manufacturing Organizations
• 13.4. Market Value Forecast By End-user by Technology, 2017-2031
  • 13.4.1. Pharmaceutical Companies
    • 13.4.1.1. CRISPR Knockout
    • 13.4.1.2. CRISPR Knockin
    • 13.4.1.3. Random Insertions
    • 13.4.1.4. Large, Targeted Insertions
    • 13.4.1.5. ES Cell Modification (Homologous Recombination)
    • 13.4.1.6. Others
  • 13.4.2. Biotechnology Companies
    • 13.4.2.1. CRISPR Knockout
    • 13.4.2.2. CRISPR Knockin
    • 13.4.2.3. Random Insertions
    • 13.4.2.4. Large, Targeted Insertions
    • 13.4.2.5. ES Cell Modification (Homologous Recombination)
    • 13.4.2.6. Others
  • 13.4.3. Academic and Research Facilities
    • 13.4.3.1. CRISPR Knockout
    • 13.4.3.2. CRISPR Knockin
    • 13.4.3.3. Random Insertions
    • 13.4.3.4. Large, Targeted Insertions
    • 13.4.3.5. ES Cell Modification (Homologous Recombination)
    • 13.4.3.6. Others
  • 13.4.4. Contract Research and Manufacturing Organizations
    • 13.4.4.1. CRISPR Knockout
    • 13.4.4.2. CRISPR Knockin
    • 13.4.4.3. Random Insertions
    • 13.4.4.4. Large, Targeted Insertions
    • 13.4.4.5. ES Cell Modification (Homologous Recombination)
    • 13.4.4.6. Others
• 13.5. Market Value Forecast By Country/Sub-Region, 2017-2031
  • 13.5.1. GCC Countries
  • 13.5.2. South Africa
  • 13.5.3. Rest of Middle East & Africa
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Technology
  • 13.6.2. By End-user
  • 13.6.3. By End-user by Technology
  • 13.6.4. By Country/Sub-Region

14. Competition Landscape

• 14.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 14.2. Market Share Analysis By Company (2021)
  • 14.2.1. Global
  • 14.2.2. North America
  • 14.2.3. Europe
  • 14.2.4. By Asia-Pacific
  • 14.2.5. By Latin America
  • 14.2.6. By Middle East & Africa
• 14.3. Company Profiles
  • 14.3.1. BIOCYTOGEN
    • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.1.2. Product Portfolio
    • 14.3.1.3. SWOT Analysis
    • 14.3.1.4. Strategic Overview
  • 14.3.2. Charles River Laboratories
    • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.2.2. Product Portfolio
    • 14.3.2.3. SWOT Analysis
    • 14.3.2.4. Strategic Overview
  • 14.3.3. Cyagen Biosciences
    • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.3.2. Product Portfolio
    • 14.3.3.3. SWOT Analysis
    • 14.3.3.4. Strategic Overview
  • 14.3.4. Gempharmatech
    • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.4.2. Product Portfolio
    • 14.3.4.3. SWOT Analysis
    • 14.3.4.4. Strategic Overview
  • 14.3.5. genOway
    • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.5.2. Product Portfolio
    • 14.3.5.3. SWOT Analysis
    • 14.3.5.4. Strategic Overview
  • 14.3.6. ingenious targeting laboratory
    • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.6.2. Product Portfolio
    • 14.3.6.3. SWOT Analysis
    • 14.3.6.4. Strategic Overview
  • 14.3.7. Merck KGaA
    • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.7.2. Product Portfolio
    • 14.3.7.3. SWOT Analysis
    • 14.3.7.4. Strategic Overview
  • 14.3.8. Ozgene Pty Ltd.
    • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.8.2. Product Portfolio
    • 14.3.8.3. SWOT Analysis
    • 14.3.8.4. Strategic Overview
  • 14.3.9. Taconic Biosciences, Inc.
    • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.9.2. Product Portfolio
    • 14.3.9.3. SWOT Analysis
    • 14.3.9.4. Strategic Overview
  • 14.3.10. PolyGene AG
    • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.10.2. Product Portfolio
    • 14.3.10.3. SWOT Analysis
    • 14.3.10.4. Strategic Overview
  • 14.3.11. THE JACKSON LABORATORY
    • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.11.2. Product Portfolio
    • 14.3.11.3. SWOT Analysis
    • 14.3.11.4. Strategic Overview
  • 14.3.12. Yale School of Medicine
    • 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.12.2. Product Portfolio
    • 14.3.12.3. SWOT Analysis
    • 14.3.12.4. Strategic Overview
  • 14.3.13. University of North Carolina
    • 14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.13.2. Product Portfolio
    • 14.3.13.3. SWOT Analysis
    • 14.3.13.4. Strategic Overview
  • 14.3.14. University of Nebraska Medical Center
    • 14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.14.2. Product Portfolio
    • 14.3.14.3. SWOT Analysis
    • 14.3.14.4. Strategic Overview
  • 14.3.15. Monash University
    • 14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.15.2. Product Portfolio
    • 14.3.15.3. SWOT Analysis
    • 14.3.15.4. Strategic Overview
  • 14.3.16. UMass Chan Medical School
    • 14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.16.2. Product Portfolio
    • 14.3.16.3. SWOT Analysis
    • 14.3.16.4. Strategic Overview
  • 14.3.17. University of Bonn
    • 14.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.17.2. Product Portfolio
    • 14.3.17.3. SWOT Analysis
    • 14.3.17.4. Strategic Overview
  • 14.3.18. Columbia University
    • 14.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.18.2. Product Portfolio
    • 14.3.18.3. SWOT Analysis
    • 14.3.18.4. Strategic Overview
  • 14.3.19. The University of Arizona
    • 14.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.19.2. Product Portfolio
    • 14.3.19.3. SWOT Analysis
    • 14.3.19.4. Strategic Overview